Siste måned
30 dager
0
NETTO POSISJON (NOK)
Handler
3
Kjøp
0
Salg
0
6 måneder
180 dager
+707 424
NETTO POSISJON (NOK)
Handler
7
Kjøp
707 424
Salg
0
Historikk
ℹ️ Om innsidehandel
Primærinnsidere er personer med ledelsesansvar og deres nærstående. Meldeplikt inntrer når transaksjoner når EUR 5 000 i et kalenderår.
Meldefrist: umiddelbart, senest tre virkedager. Handelsforbud 30 dager før pliktig finansiell rapportering.
Transaksjoner
Mer info 👉
| Dato | Innsider | Antall | Pris | Verdi |
|---|---|---|---|---|
| 30.01.2026 |
Barbara Krebs-Pohl
Chair of the Board
|
300 000 | - | - |
| 30.01.2026 |
Susanne Stuffers
Board Member
|
150 000 | - | - |
| 30.01.2026 |
John Beadle
Board Member
|
150 000 | - | - |
| 24.11.2025 |
Michael Engsig
Chief Executive Officer
|
46 356 | 2.16 | 100 129 |
| 10.10.2025 |
Louise Stubbe
Chief Legal Officer
|
1 200 000 | - | - |
| 10.10.2025 |
Susanne Stuffers
Chair of the Board
via Ubiquity AS
|
280 000 | 1.81 | 507 155 |
| 10.10.2025 |
Michael Engsig
Chief Executive Officer
|
55 944 | 1.79 | 100 140 |
Pressemeldinger
| Dato | Melding |
|---|---|
| 30.01.2026 |
Nykode Therapeutics - Grant of share options
Oslo, Norway, January 30, 2026 - Reference is made to the Extraordinary General Meeting (EGM) in Nykode Therapeutics ASA held on January 21, 2026, whe...
|
| 24.11.2025 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Oslo, Norway, November 24, 2025 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 46,356 shares...
|
| 10.10.2025 |
Nykode Therapeutics – Grant of Share Options
Oslo, Norway, October 10, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and develo...
|
| 10.10.2025 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Ubiquity AS has today acquired 280,000 shares in Nykode Therapeutics ASA at an average price of NOK 1.8113 per share. Susanne Stuffers, Chair of the B...
|
| 10.10.2025 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Oslo, Norway, October 10, 2025 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 55,944 shares ...
|